CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-03-08): Leptin helpful in non-alcoholic steatohepatitis

Drug & Device Development

Leptin helpful in non-alcoholic steatohepatitis

Last Updated: 2013-03-08 13:26:21 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Recombinant human methionyl leptin (metreleptin) appears highly effective for non-alcoholic steatohepatitis (NASH) in lipodystrophy patients with hypoleptinemia, a new paper says.

NASH is common not just in obesity but also in lipodystrophy syndromes. But "unlike obese patients, individuals with lipodystrophy are deficient in the hormone leptin, and thus leptin replacement with metreleptin is a promising therapy for the metabolic complications of lipodystrophy," senior author Dr. Philip Gorden told Reuters Health by email.

Dr. Gorden of the National Institutes of Health, Bethesda, Maryland, and colleagues reported on an open-label prospective study of leptin therapy in patients with inherited and acquired lipodystrophy, online February 22 in The Journal of Hepatology.

Patients were recruited worldwide. All 50 had liver biopsies at baseline and 27 did so following leptin replacement.

At baseline, 88% of patients met criteria for NASH. This proportion had fallen to 33% after an average 25.8 months of treatment. Steatosis mean score fell from 1.8 to 0.9. Ballooning injury scores were reduced from 1.2 to 0.4.

The authors report that nonalcoholic fatty liver disease scores also fell by a significant 42%, with the decrease "paralleled by significant reductions in metabolic parameters, including triglycerides, fasting glucose, hemoglobin A1c and transaminases."

Although the researchers were unable to show an improvement in fibrosis, those patients remained stable. "Importantly", say the investigators, "there was no worsening of fibrosis while on leptin therapy.

Given the lack of a control group and the small numbers, the authors say they can't establish a definite causative relationship between the improvement and metreleptin therapy. The improvements in NASH scores may have been spontaneous, they say.

However, they note, unlike patients with obesity-associated nonalcoholic fatty liver disease, "lipodystrophic patients cannot substantially alter the course of their disease by lifestyle modification without metreleptin therapy."

"The present paper," Dr. Gorden concluded, "demonstrates that therapy with metreleptin not only improves diabetes and lipids, but also significantly improves non-alcoholic steatohepatitis in these patients."

SOURCE: http://bit.ly/Zm1H7s

J Hepatol 2013.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.